- Home
- OKYO vs RNTX Comparison
OKYO vs RNTX Comparison
Compare OKYO & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OKYO
- RNTX
- Stock Information
- Founded
- OKYO 2007
- RNTX 2001
- Country
- OKYO United Kingdom
- RNTX United States
- Employees
- OKYO N/A
- RNTX N/A
- Industry
- OKYO Biotechnology: Biological Products (No Diagnostic Substances)
- RNTX Biotechnology: Pharmaceutical Preparations
- Sector
- OKYO Health Care
- RNTX Health Care
- Exchange
- OKYO Nasdaq
- RNTX Nasdaq
- Market Cap
- OKYO 37.0M
- RNTX 40.3M
- IPO Year
- OKYO 2022
- RNTX N/A
- Fundamental
- Price
- OKYO $2.41
- RNTX $1.38
- Analyst Decision
- OKYO Strong Buy
- RNTX
- Analyst Count
- OKYO 1
- RNTX 0
- Target Price
- OKYO $7.00
- RNTX N/A
- AVG Volume (30 Days)
- OKYO 213.3K
- RNTX 24.8K
- Earning Date
- OKYO 08-12-2025
- RNTX 08-13-2025
- Dividend Yield
- OKYO N/A
- RNTX N/A
- EPS Growth
- OKYO N/A
- RNTX N/A
- EPS
- OKYO N/A
- RNTX N/A
- Revenue
- OKYO N/A
- RNTX N/A
- Revenue This Year
- OKYO N/A
- RNTX N/A
- Revenue Next Year
- OKYO N/A
- RNTX N/A
- P/E Ratio
- OKYO N/A
- RNTX N/A
- Revenue Growth
- OKYO N/A
- RNTX N/A
- 52 Week Low
- OKYO $0.81
- RNTX $1.35
- 52 Week High
- OKYO $3.11
- RNTX $4.40
- Technical
- Relative Strength Index (RSI)
- OKYO 58.01
- RNTX N/A
- Support Level
- OKYO $2.05
- RNTX N/A
- Resistance Level
- OKYO $2.49
- RNTX N/A
- Average True Range (ATR)
- OKYO 0.31
- RNTX 0.00
- MACD
- OKYO -0.01
- RNTX 0.00
- Stochastic Oscillator
- OKYO 44.44
- RNTX 0.00
About OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.